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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYAdult skeletal muscle stem cells, or satellite cells (SCs), regenerate functional muscle following transplantation into injured or diseased
tissue. To gain insight into human SC (huSC) biology, we analyzed transcriptome dynamics by RNA sequencing of prospectively isolated
quiescent and activated huSCs. This analysis indicated that huSCs differentiate and lose proliferative potential whenmaintained in high-
mitogen conditions ex vivo. Further analysis of gene expression revealed that p38 MAPK acts in a transcriptional network underlying
huSC self-renewal. Activation of p38 signaling correlated with huSC differentiation, while inhibition of p38 reversibly prevented differ-
entiation, enabling expansion of huSCs. When transplanted, expanded huSCs differentiated to generate chimeric muscle and engrafted
as SCs in the sublaminar niche with a greater frequency than freshly isolated cells or cells cultured without p38 inhibition. These studies
indicate characteristics of the huSC transcriptome that promote expansion ex vivo to allow enhanced functional engraftment of a
defined population of self-renewing huSCs.INTRODUCTION
In adult mammals, skeletal muscle is regenerated by a pop-
ulation of tissue-resident muscle stem cells, also known
as satellite cells (SCs). Quiescent SCs in uninjured muscle
are activated in response to injury or disease (Mauro,
1961). Upon activation, SCs undergo a proliferative expan-
sion, yielding a pool of muscle progenitor cells that sub-
sequently fuse to form functional multinucleate muscle
fibers (Snow, 1978). In mice, transplanted SCs are capable
of engrafting as constituents ofmultinucleatemuscle fibers
or as self-renewed muscle stem cells (Collins et al., 2005).
When transplanted into dystrophin-deficient mdx mice,
wild-type SC-derived muscle progenitors fuse to regenerat-
ing host fibers and restore dystrophin expression (Karpati
et al., 1989; Partridge et al., 1989). Transplantation of
allogeneic muscle progenitors or of genetically corrected
autologous muscle progenitors is, therefore, a promising
approach to treating inherited muscle diseases, such as
Duchenne muscular dystrophy. However, owing to a
limited understanding of human SC (huSC) biology, it is
still unclear as to what extent findings from mouse studies
will translate to human cell-based therapies.
A major barrier to the development of stem cell-based
therapies is the inability to generate large numbers of trans-
plantable stem cells with the potential to both self-renew
and differentiate. In general, the contribution of donorStem CellSCs to muscle regeneration has been shown to correlate
with the number of cells transplanted (Bosnakovski et al.,
2008; Sacco et al., 2008). Although transplantation of SCs
in association with donor muscle fibers has been shown to
enhance engraftment efficiency (Collins et al., 2005; Hall
et al., 2010), biopsies, surgical specimens, and post-mortem
tissuedonations are expected toyield fewcells relative to the
number that will be required for therapeutic huSC engraft-
ment, and techniques for the growth and manipulation of
progenitor cells ex vivo are, therefore, expected to be an
important element of cell-based therapies. Culturing huSCs
also will be important for therapies involving gene correc-
tion of autologous cells, which will need to be engineered,
selected, and expanded ex vivo. These technical challenges
are compounded by the loss of regenerative potential that
occurs when SCs are grown in culture. In studies of mouse
SCs, expansion in culture for as little as 3 days led to a 10-
fold reduction in engraftment effiency (Montarras et al.,
2005). An even more marked reduction in transplantation
linked to cell culture was observed in comparisons of
cultured and freshly isolated caninemuscle progenitor cells
(Parker et al., 2012). Although the transplantation efficiency
of muscle progenitors from model organisms has been
enhanced previously by manipulation of Notch signaling
(Parker et al., 2012) or substrate elasticity (Gilbert et al.,
2010), there are no techniques currently for the expansion
of self-renewing huSCs ex vivo.Reports j Vol. 5 j 621–632 j October 13, 2015 j ª2015 The Authors 621
Our limited understanding of huSC biology can be attrib-
uted in part to the difficulty of obtaining tissue samples and
of isolating a pure population of huSCs (Boldrin et al.,
2010). By comparison, techniques for the prospective isola-
tion of mouse SCs have identified a well-defined myogenic
SC population and have enabled extensive characteriza-
tion of themolecular regulation of their quiescence, activa-
tion, and differentiation (Bosnakovski et al., 2008; Collins
et al., 2005; Fukada et al., 2007; Liu et al., 2013; Montarras
et al., 2005; Sherwood et al., 2004). Previous studies have
used prospective isolation of mononuclear cell types with
distinct surface protein expression to define subsets of
myogenic and non-myogenic cells in human muscle.
These studies have found that a myogenic population re-
sides within cells expressing CD56 (NCAM) (Bareja et al.,
2014; Pisani et al., 2010a, 2010b; Zheng et al., 2007). Zheng
et al. have identified both CD56+CD34 and CD56+CD34+
subsets with myogenic potential. The CD56+CD34+ subset
is thought to represent a myoendothelial population with
the capacity to differentiate into myogenic, chondrogenic,
or osteogenic lineages (Zheng et al., 2007). A similar study
of myogenic potential within muscle-resident human cell
populations showed that a CD56+CD34+ population of bi-
potent progenitors can give rise to both myogenic and adi-
pogenic cell types in vitro (Pisani et al., 2010a). In a second
study, the same authors confirmed that both CD56+CD34+
and CD56+CD34 cells have myogenic potential, but only
the latter is restricted to a myogenic fate (Pisani et al.,
2010b). More recently, Bareja et al. (2014) used CD34 as a
negative selection marker for identification of a myogenic
huSC within the CD56+ population.
Thus, there remains a lack of consensus regarding the
identity of huSCs and further studies are required to assess
the myogenic identity of prospectively isolated popula-
tions at the resolution of single cells. Notably, previous pro-
spective isolation studies assessed the myogenic potential
of purified cell populations by the analysis of human-spe-
cific gene expression in engrafted muscle tissue, but did
not study their stem cell potential by evaluating the self-
renewal of these populations in vivo. Nonetheless, the
dual potential for self-renewal and differentiation remains
the defining feature of stem cells. Therefore, further charac-
terization of the identity and stem cell characteristics of
huSCs is essential for developing insight into their mecha-
nisms of self-renewal.
To further our understanding of huSC biology, we used
prospective cell isolation, RNA sequencing (RNA-seq) ana-
lyses, and cell transplantation to study a defined popula-
tion of human myogenic progenitors with the potential
to self-renew. This information was leveraged to identify
changes in the molecular phenotype and self-renewal po-
tential within the purified huSC population. Specifically,
we mapped a core transcription factor regulatory network622 Stem Cell Reports j Vol. 5 j 621–632 j October 13, 2015 j ª2015 The Aof self-renewal, and we established an essential role for
p38 mitogen-activated protein kinase (MAPK) in the regu-
lation of huSC regenerative capacity akin to that observed
in mouse. Reversible pharmacologic inhibition of p38 in
cultured huSCs resulted in a gene expression program
consistent with the promotion of huSC self-renewal, and
it allowed for expansion of a population of huSCs ex vivo
with enhanced self-renewal and engraftment potential.RESULTS
As the starting point of this study, we prospectively isolated
huSCs from surgical specimens of skeletal muscle using
fluorescence-activated cell sorting (FACS) to analyze cell-
surface protein expression. To identify huSC surface mar-
kers, we sequentially screened known markers of mouse
SCs and huSCs by analyzing extracellular protein expres-
sion in PAX7-expressing SCs associated with human mus-
cle fiber explants (Figure S1A). Like mouse SCs, huSCs
expressed b1-integrin (ITGB1), but did not express the
endothelial marker CD31 or the hematopoietic marker
CD45 (Sherwood et al., 2004). We observed that huSCs,
in contrast to mouse SCs (Montarras et al., 2005; Sherwood
et al., 2004), did not express detectable CD34. Furthermore,
we found that the epidermal growth factor receptor (EGFR),
which is expressed bymouse SCs (Golding et al., 2007) and
exhibits a rapid decrease in expression early in the process
of differentiation (Leroy et al., 2013), also was expressed by
human fiber-associated SCs. Taken together, our studies
defined huSCs as CD34CD31CD45 cells that can be
further specified as a population that expresses ITGB1
and EGFR (Figures 1A and S1A). Using this surface protein
signature, huSCs could be prospectively isolated from all
muscles tested, including latissimus dorsi, serratus anterior,
and rectus abdominis (Figure S1B).
To analyze the purity of cells within the putative huSC
population, we quantified the percentage of cells express-
ing PAX7 (Figure 1B), which serves as a marker of huSCs.
This analysis revealed that 96% ± 2% (n = 8) of cells in
the huSC population express PAX7 (Figure 1B), while no
PAX7-expressing cells were observed in the remaining
huSC-depleted population, which consisted of all cells ex-
pressing CD34, CD31, or CD45 (Figure S1C). These data
indicate that the sorting strategy highly enrichesmyogenic
cells. As an additional analysis of the myogenic identity of
the sorted cell populations, single-cell-derived clones were
analyzed for expression of myogenic genes (Figure S1D).
Although 100% of cells in the putative huSC-derived pop-
ulation yielded clones that expressed PAX7, no PAX7-ex-
pressing clones were derived from the remaining huSC-
depleted cells. The myogenic identity of purified huSCs
also was evaluated by analyzing the expression of a suiteuthors
Figure 1. Identification and Prospective Isolation of HuSCs
(A) Cell-sorting scheme used to isolate huSCs by FACS for a representative specimen of latissimus dorsi muscle. Red gates indicate sub-
populations containing huSCs. Numbers indicate percentage of total events falling within each gate; given error represents SD (n = 15).
(B) Immunofluorescence (IF) analysis of PAX7 expression in purified huSCs at low (top) and high (bottom) magnification 3 days after
isolation. Cells were stained with antibodies against PAX7 and with DAPI to identify nuclei.
(C) qRT-PCR analysis of PAX7, PAX3, MYF5, MYOD, MYOG, and MEF2C mRNA levels in the huSC and huSC-depleted cell populations after a
period of 7 days in culture is shown (n = 4). Error bars represent SD. *p < 0.05, **p < 0.01, ***p < 0.001.ofmyogenic transcription factors relative to huSC-depleted
cells (Figure 1C). In this analysis, cultured huSCs expressed
significantly more PAX7, PAX3,MYF5,MYOD,MYOG, and
MEF2C than the remaining huSC-depleted population. We
also observed that a subset of activated huSC progeny fused
to form multinucleate myotubes when cultured to 90%
confluency (Figure S1E). In contrast, the huSC-depleted
population of cells grown under the same conditions did
not exhibit signs of myogenesis in culture (Figure S1F),
further indicating that the purification strategy efficiently
enriches myogenic cells.
We next aimed to characterize changes in huSCs during
ex vivo culture, which, in mice, results in a marked reduc-
tion in the capacity for tissue regeneration and self-renewal
upon subsequent transplantation (Gilbert et al., 2010;
Montarras et al., 2005). For this analysis, we used a basal
culture medium supplemented with fetal bovine serum
(FBS) and with insulin, transferrin, and selenium (Roche-
teau et al., 2012). Additional specific growth factors were
not included to limit perturbations that might confound
the interpretation of stem cell behavior ex vivo. To study
the behavior of huSCs during their growth in culture,
we first used time-lapse microscopy to observe purified
cells beginning shortly after prospective isolation. These
real-time studies of huSCs revealed that, upon isolation,Stem Cellinitially quiescent cells undergo a process of activation in
which they initially grow in size and becomemotile (Movie
S1). HuSCs first divided, on average, 83.3 ± 14.1 hr post-
isolation (Figure S1G). Activated huSC progeny undergo a
second cell division that occurs, on average, 25.5 ± 5.7 hr
later (Figure S1H). Interestingly, the time to first cell divi-
sion and the time between the first and second cell divi-
sions were considerably longer for huSCs than for mouse
SCs studied in similar conditions (Rodgers et al., 2014).
To further characterize the behavior of huSCs ex vivo, we
maintained SC cultures and analyzed their growth over a
period of 3 weeks. Cells were serially passaged to maintain
cultures below 40%of confluency. In four independent cul-
tures, we observed that freshly isolated cells underwent a
period of exponential growth between 4 and 9 days after
isolation, typical of isolated murine SCs between 3 and
5 days after isolation. After the exponential growth phase,
the huSCs entered a phase of linear growth kinetics (Fig-
ure S1I), and this pattern persisted for the remainder of
the observed period in culture. Thus, huSCs give rise to a
pool of proliferating progeny in culture, which as a popula-
tion exhibits a progressive slowing of the growth rate.
To study the molecular regulation of the phenotypic
transition that occurs in activated huSCs, and as a resource
for future studies of huSC-mediated myogenesis, weReports j Vol. 5 j 621–632 j October 13, 2015 j ª2015 The Authors 623
Figure 2. Transcriptome Profiles of Pro-
spectively Isolated Quiescent and Acti-
vated HuSCs
(A) Schematic shows RNA-seq analysis of
prospectively isolated quiescent and ex vivo
activated huSCs.
(B) Representative RNA-seq analysis shows
quiescent (blue) and activated (red) muscle
SCs isolated from latissimus dorsi muscle.
(C) RNA-seq analysis shows MYF5 expression
in quiescent and activated huSCs.
(D) RNA-seq analysis shows expression
of differentiation-associated transcription
factors in quiescent and activated huSCs.
(E) Quantification of DUSP1 expression in
quiescent and activated huSCs based on
RNA-seq analyses is shown.
(F) Transcription factor regulatory network
of huSCs constructed from analysis of dif-
ferential gene expression in quiescent and
activated huSCs (see Experimental Pro-
cedures for details). Highlighted in red are
transcription factors with known associa-
tions with the p38 MAPK signaling pathway;
highlighted in green are myogenic regula-
tory factors. The strength of evidence for a
given interaction is reflected by the hue of
the edge connecting two nodes, with darker
edges indicating greater confidence. For
RNA-seq data, reads from two biological
replicates per condition are shown mapped
to the reference genome. The number of
sequenced fragments per kilobase of exon
per million fragments mapped (FPKM) in
each condition is shown for individual
genes (n = 2 biological replicates per con-
dition). Error bars represent SD.generated transcriptome profiles using RNA-seq of both
freshly purified, quiescent huSCs and activated huSCs,
the latter having been cultured for 7 days (Figure 2A). We
chose to analyze cells following 7 days in culture in order
to capture the population in a fully activated state,
knowing that at 7 days the population of cultured huSCs
is in a phase of exponential growth (Figure S1I) and thema-
jority of cells in the population has undergone at least one
division (Figures S1G and S1H; Movie S1). Relative to acti-
vated cells, freshly isolated quiescent huSCs express tran-
scripts, such as NFIA, NDRG2, and CHRDL2, which also
are expressed in quiescent, undifferentiated murine SCs
(Fukada et al., 2007; Liu et al., 2013; Figure 2B). Quiescent
huSCs also express high levels of MYF5, which decrease in
activated huSCs (Figure 2C). Consistent with our previous624 Stem Cell Reports j Vol. 5 j 621–632 j October 13, 2015 j ª2015 The Acharacterizations of mouse SCs activated in response to
injury in vivo (Liu et al., 2013), activated huSCs upregu-
lated genes associated with cell proliferation andmyogenic
differentiation: unbiased analysis of the genes that ex-
hibited greater than 10-fold increased expression in acti-
vated huSCs relative to quiescent huSCs revealed enrich-
ment for genes associated with the mitotic cell cycle
(gene ontology [GO]:0000278; p = 6.5 3 109) and muscle
organ development (GO:0007517; p = 1.531010). Further-
more, cultured huSCs expressed differentiation-associated
transcription factors such as MYOG and MEF2C (Fig-
ure 2D). Cultured huSCs as a population also upregulated
genes required for myofibril assembly and muscle contrac-
tion (e.g., MYH3, CACNG1, and MYL2) (Figure S2A), sup-
porting the conclusion that activated huSCs initiate authors
transcriptional program of myogenic differentiation even
under high-mitogen growth conditions and sub-confluent
cell density.
As an initial application of our RNA-seq datasets for dis-
covery of regulatory mechanisms in huSCs, we compared
transcriptomes of quiescent huSCs to those of activated
huSCs to identify loci that were differentially expressed.
In quiescent huSCs, we identified 998 highly expressed
genes, including 133 loci annotated as transcription fac-
tors, 66 as receptors, and 56 as signaling molecules by the
PANTHER gene ontology database (Table S1). Importantly,
several known quiescent rodent SC-associated markers,
such as CALCR, CXCR4, and SPRY1, were identified in
this analysis, suggesting that the method was reliable in
its identification of enriched transcripts. The same analysis
of transcripts enriched in activated huSCs highlighted 708
transcripts, including 29 annotated transcription factors,
40 receptors, and 28 signaling molecules (Table S1). Here
again we found many interesting and unanticipated tran-
scripts and were reassured to find several known important
regulators of myogenic differentiation, including MYOD1,
MYOG, and MEF2C.
We further analyzed our transcriptional profiling data to
computationally define biological processes over-repre-
sented among lists of differentially expressed genes. With
this analysis, we identified a number of significantly en-
riched (p < 0.05) biological processes and their associated
genes in both quiescent and activated huSCs (Tables S2
andS3). In activatedhuSCs,we identifiedhundreds of genes
associated with muscle contraction, muscle development,
mitosis, and the cell cycle, among other processes. In quies-
cent huSCs, we identified numerous genes linked to tran-
scriptional regulation, signal transduction, and cell-cycle
control. Of particular interest, several important compo-
nents of the Notch signaling pathway were identified as
differentially expressed genes in this analysis. The Notch
signaling pathway is a regulator of various aspects of rodent
SC quiescence and activation, andNotch transcriptional ac-
tivity is required for the maintenance of quiescence in
mouse SCs (Bjornson et al., 2012; Conboy and Rando,
2002;Mourikis et al., 2012). In culturedhuSCs,we identified
in particular downregulation of expression of the Notch re-
ceptor NOTCH3 and of the canonical Notch target genes
HEY1, HEY2, and HES1 (Table S3), supporting the model
arising from studies ofmouse SCs thatNotch signalingplays
criticial roles in the functionof undifferentiatedmuscle pro-
genitors. These analyses suggest that networks of tran-
scribed genes with specific roles in quiescent and activated
huSCs can be efficiently identified within RNA-seq data.
To take further advantage of these RNA-seq datasets of
huSCs,we sought to identify signaling pathways governing
processes of proliferative expansion, self-renewal, and dif-
ferentiation in order to seek genes and pathways whoseStem Cellmanipulation might be valuable for therapeutic applica-
tions of prospectively isolated huSCs. Our analysis of tran-
scription in huSCs revealed that, among the genes that are
differentially expressed by activated huSCs relative to
quiescent huSCs, genes associated with MAPK signaling
are significantly enriched (p = 1.2 3 103). Among these
genes, we noted a 35-fold decrease upon huSC activation
in culture in the expression ofDUSP1 (Figure 2E), which en-
codes a dual-specificity phosphatase that dephosphory-
lates and, thus, inactivates p38 MAPK. This finding was
of particular interest to us, given the implication of p38
MAPK signaling in the regulation of rodentmuscle progen-
itor differentiation in the context of muscle regeneration
(Lluı´s et al., 2006; Shi et al., 2010).
With our RNA-seq data, we constructed a core transcrip-
tion factor network regulating the phenotypic changes
upon culturing quiescent huSCs using published studies
to identify relationships among known transcription fac-
tors that were computationally predicted to regulate genes
that were differentially expressed by quiescent and acti-
vated huSCs (Figure 2F). In addition to the myogenic regu-
latory factors MYF5, MYOD1, MYOG, and MRF4, this
network included a number of transcription factors regu-
lated by p38, including HIF1A, PTEN, GATA4, SP3,
SMAD3, NF-kB, VDR, AR, and MYC. To measure the extent
of p38 activation in huSCs in vivo and in vitro, we analyzed
the levels of phosphorylated (activated) p38 (p-p38).
Although p-p38 was absent from quiescent SCs in histolog-
ic sections of human skeletal muscle, we observed robust
p38 phosphorylation in activated huSCs in culture (Fig-
ure 3A). The activation of p38 in activated huSCs, as as-
sessed by its phosphorylation, was independent of the
density at which cells were cultured (Figures S2B and
S2C). Taken together, these data support a model in which
p38 MAPK is activated during ex vivo huSC growth, con-
current with a loss of proliferative potential and expression
of differentiation-associated genes.
To determine whether the inhibition of p38 MAPK
in activated huSCs could maintain their proliferative
potential and prevent expression of genes formyogenic dif-
ferentiation, we grew the cells in the presence of a small
molecule p38 inhibitor (p38i; SB 203580) and analyzed
both their transcriptional and functional properties.
Though various p38 inhibitors have been developed, SB
203580 was selected for this study because its targeting
specificity has been studied extensively (Cuenda and Co-
hen, 1999; Davies et al., 2000; Eyers et al., 1998; Gum
et al., 1998). Given previous observations of dose-depen-
dent cell growth inhibition by p38 inhibitors in trans-
formed muscle progenitor cell lines (Jones et al., 2005),
we first studied the effects of varying doses of p38 inhibitor
on PAX7 expression and cell proliferation in activated
huSCs. PAX7 expression, which is correlated with theReports j Vol. 5 j 621–632 j October 13, 2015 j ª2015 The Authors 625
Figure 3. Regulation of p38 MAPK
Signaling Controls HuSC Fate
(A) IF analysis shows activated p-p38 in
quiescent huSCs in vivo (top) and activated
huSCs ex vivo (bottom).
(B) RNA-seq analysis of markers of terminal
differentiation in control untreated (red)
and p38i-treated (green) activated huSCs.
Sequencing reads from two biological rep-
licates per condition are shown mapped to
the reference genome. The FPKM in each
condition is shown for individual genes (n =
2 biological replicates per condition).
(C) Representative fluorescence microscopy
analysis of EdU incorporation in control
and p38i-treated huSCs cultured for 9 days.
The percentage of huSCs in each condition
incorporating EdU during a 1-hr pulse was
quantified (n = 4). Error bars represent SD.
**p < 0.01.undifferentiated muscle progenitor fate (Rocheteau et al.,
2012), exhibited a dose-dependent increase as the concen-
tration of p38i was increased from 0 to 10 mM, but did not
significantly change at concentrations beyond 10 mM (Fig-
ure S3A). We next examined the effect of varying concen-
trations of p38i on the rate of proliferation of undifferenti-
ated cells by analyzing huSCs cultured with or without
inhibitor for only 3 days post-isolation. Although concen-
trations of p38i up to 10 mM showed equivalent rates of
EdU incorporation, when cells were cultured with 20 mM
p38i, the frequency of EdU incorporation was reduced
significantly (Figure S3B). Because 10 mM p38i maximally
induced expression of the stem cell marker PAX7 without
significantly limiting cell proliferation, this drug concen-
tration was used for all subsequent studies of cell fate.626 Stem Cell Reports j Vol. 5 j 621–632 j October 13, 2015 j ª2015 The ATo test for effective inhibition of p38 activity in SC cul-
tures treated with 10 mM p38i, we quantified the amount
of p38 target protein phosphorylation in control and
p38i-treated cultures. These studies revealed marked de-
creases in the levels of phosphorylation of two p38 sub-
strates, phopsho-HSP27 (Ser82) (Larsen et al., 1997) and
phospho-GYS1 (Ser645) (Kuma et al., 2004), in the pres-
ence of p38i (Figures S3C–S3F). Consistent with a model
in which p38 activity prevents myogenic lineage progres-
sion, p38i-treated cells expressed levels of MYOG, MYH3,
and MYL2, for example, that were significantly reduced
in comparison to untreated cells (Figure 3B). We observed
similar suppression of MYOG expression by SB 203580
and an alternative, specific p38 inhibitor, SB 239063,
further supporting the conclusion that pharmacologicuthors
manipulation of p38 in huSCs limits the expression of dif-
ferentiation-associated genes (Figures S3G and S3H). Cells
cultured in the presence of p38i also exhibited markedly
diminished expression of MYOG and myosin heavy chain
(MyHC) protein compared to controls (Figures S3I and S3J).
Unbiased analysis of the set of genes that exhibited
decreased expression due to p38i treatment revealed en-
richment for genes associated with muscle contraction
(GO:0006936; p = 3.7 3 1015) and muscle organ develop-
ment (p = 2.23 105). Although p38 inhibition blocked SC
differentiation, we found that the expression of MYOD1
was not decreased in treated cells (Figure S3K), consistent
with our findings in murine SCs of high levels of Myod1
expression in quiescent cells (Liu et al., 2013). The bulk
of p38i-treated cultured huSCs also exhibited undimin-
ished expression of the myogenic regulatory factor MYF5
relative to untreated cells (Figure S3L). Pharmacologic inhi-
bition of p38 MAPK signaling thus maintained cultured
huSCs in an undifferentiated state ex vivo.
As a first test of the ability of p38 inhibition to maintain
the proliferative potential of huSCs as undifferentiated
cells, we measured the proliferation index of huSCs
cultured in the presence or absence of p38i for 9 days by
monitoring incorporation of EdU. While only 4.4% ±
0.4% of untreated cells incorporated EdU during a 1-hr
pulse, 27% ± 2% of p38i-treated cells incorporated EdU
(Figure 3C). Analysis of metaphase spreads of p38i-treated
huSCs revealed normal chromosome number in 100% of
cells after ten passages (Figure S3M). Consistent with the
observation of increased EdU incorporation in p38i-treated
huSCs after 9 days in culture, expression of genes associ-
ated with DNA replication and cell division, including
MKI67, NDC80, AURKB, and RFC4, was increased in p38i-
treated cells relative to untreated cells in the analyses of
RNA-seq data (Figure S3N). Growth curves of p38i-treated
huSCs maintained in culture for 3 weeks demonstrated
preservation of exponential growth kinetics and massive
expansion of the treated huSC cultures in comparison to
parallel untreated control cultures from the same donor
(Figure S3O). Thus, blocking huSC differentiation by inhib-
iting p38 maintains cells in an undifferentiated state in
which they continued to proliferate without evidence of
genetic instability.
Although inhibition of p38 MAPK signaling prevented
spontaneous differentiation of huSCs ex vivo, this effect
was reversible. After 2 weeks of expansion in the pres-
ence of p38i, the drug was chased for a period of
5 days, during which we observed a significant increase
in MYOG expression (Figure S4A). After the 5-day chase,
we also observed terminal differentiation of expanded
cells into multinucleate MyHC-expressing myotubes
(Figure S4B). These data indicate that the inhibition of
huSC differentiation by p38i is reversible and that cellsStem Cellexpanded with p38i retain the ability to terminally
differentiate.
To test directly the self-renewal and tissue regenerative
potential of expanded huSCs in vivo, we analyzed cell
engraftment upon xenotransplantation into immunodefi-
cient mice. As adult stem cells, huSCs are expected to yield
progeny that either regenerate muscle tissue or replenish
the pool of self-renewing stem cells. In transplantation
studies, we compared the p38i-treated activated huSCs to
two control cell populations as follows: (1) freshly isolated,
uncultured quiescent huSCs; and (2) activated huSCs
grown in the absence of p38i. We first tested huSC regener-
ative potential by analyzing the expression of human-spe-
cific nuclear lamin A/C (LMNA) and human-specific ITGB1
following transplantation of huSCs into tibialis anterior
muscles. Expression of human/mouse laminin also was
used to visualize gross muscle morphology. We observed
robust engraftment of human LMNA-labeled nuclei that
correlated with the expression of human ITGB1 in muscle
fibers (Figures 4A and 4B; Figure S4C). The p38i-treated acti-
vated huSCs engrafted to form human ITGB1-expressing
chimeric muscle fibers with approximately 4-fold and 11-
fold greater efficiency than freshly isolated quiescent
huSCs and control activated huSCs, respectively (221 ±
20 chimeric fibers per muscle cross-section from p38i-
treated activated huSCs versus 49 ± 14 from quiescent
huSCs and 21 ± 13 from untreated activated huSCs; p <
0.001 in separate comparisons of each control condition
to the p38i-treated condition) (Figure 4A). Furthermore,
human-mouse chimeric muscle fibers formed by the
engraftment of p38i-expanded huSCs expressed human
dystrophin (DMD) (Figure S4D). We also analyzed ex-
panded huSC engraftment by studying fusion of huSCs en-
gineered ex vivo by adenoviral infection to express a GFP
transgene, giving rise to chimeric GFP-expressingmuscle fi-
bers in transplanted NSGmice (Figures S4E and S4F). These
analyses demonstrate as a proof-of-concept that the pro-
spectively isolated and expanded cells are genetically
manipulable and capable of expressing donor-derived
DMD in chimeric fibers.
To study the potential of transplanted huSCs to manifest
a defining stem cell property by undergoing self-renewal to
yield PAX7-expressing huSCs in vivo, we first examined the
expression of PAX7 in nuclei of unfused human cells in
recipient muscles. In this analysis, we observed PAX7-ex-
pressing nuclei of human origin that resided beneath the
basal lamina (Figure 4B; Figures S4G and S4H). To compare
quantitatively the potential of freshly isolated quiescent
huSCs, control activated huSCs, and p38i-treated activated
huSCs to engraft as mononuclear stem cells, we analyzed
the abundance of unfused, donor human cells by flow cy-
tometry. We initially confirmed that unfused donor cells
expressed PAX7 as evidence that they had formed renewedReports j Vol. 5 j 621–632 j October 13, 2015 j ª2015 The Authors 627
Figure 4. Xenotransplantation Reveals
Regenerative Potential of Expanded HuSCs
(A) Four weeks after transplantation, en-
graftment of freshly isolated quiescent
huSCs, control activated huSCs, and p38i-
treated activated huSCs was determined
by IF analysis of human-specific ITGB1
expression (magenta); 3 3 104 cells were
used for each transplant. Anti-laminin
(green) detects laminin of mouse and human
origin.
(B) Representative low-magnification (left)
and high-magnification (right) images of
engrafted p38i-treated activated huSCs
4 weeks after transplantation into mouse
muscle. The yellow arrowhead identifies a
sublaminar PAX7-expressing cell of human
origin; the yellow arrow identifies a nearby sublaminar Pax7-expressing cell of mouse origin.
(C) Representative flow cytometric analysis of human-specific ITGB1 expression in the bulk population of mononuclear cells isolated from
mouse muscle transplanted with 3 3 104 huSCs per transplant. Quantification of total mononuclear human ITGB1-expressing cells per
transplanted muscle revealed a 3.6-fold and 7.7-fold increase in engraftment of p38i-treated huSCs relative to quiescent huSCs and
untreated activated huSCs, respectively. ***p < 0.001 comparing p38i-treated activated huSCs to control activated huSCs or quiescent
huSCs (n = 4 per condition). Error bars represent SD.huSCs (Figures S4I and S4J). Comparable to the analysis of
fusion as an index of donor cell engraftment, p38i-treated
activated huSCs had approximately 3.6-fold and 7.6-fold
greater potential for engraftment as mononuclear SCs
than quiescent huSCs and control activated huSCs, res-
pectively (Figure 4C). Histological quantification of the
number of human-derived, PAX7-expressing nuclei in
cross-sections of transplanted muscle indicated a similar
enhancement of engraftment by p38i-treated activated
huSCs versus both quiescent huSCs and untreated acti-
vated huSCs.We, therefore, conclude that huSCs expanded
in culture via p38 inhibition are capable of engrafting both
as constituents of multinucleate muscle fibers and as self-
renewed mononuclear huSCs.
The analysis of skeletal muscle regeneration and SC self-
renewal following transplantation indicated that huSCs
expanded in the presence of p38i exhibited tissue regenera-
tive and self-renewal potential exceeding that of even
freshly isolated quiescent huSCs. Given that quiescent
huSCs are no more differentiated than p38i-treated cul-
tured huSCs, the incongruent engraftment of these popula-
tions was surprising because it suggested that treating
activated huSCs with p38i enhanced engraftment of the
transplanted cells in part via a mechanism that was inde-
pendent of blocking differentiation. We, therefore, sought
to identify alternative mechanisms accounting for the
enhanced self-renewal and tissue regenerative potential of
p38i-treated huSCs using our RNA-seq analyses of these
cell populations. In addition to the marked changes in
gene expression noted previously (Figure 3; Table S4), we
were intrigued to identify significant (p = 0.028) enrich-628 Stem Cell Reports j Vol. 5 j 621–632 j October 13, 2015 j ª2015 The Ament for genes associatedwith aging (GO:0007568) among
the list of genes downregulated by p38 inhibition. This
observation was particularly interesting in light of recent
studies in which treatment of old mouse SCs with p38i
was observed to rejuvenate aspects of their regenerative
function, including their potential to regenerate damaged
muscle following transplantation (Bernet et al., 2014; Cos-
grove et al., 2014).Wediscovered six aging-associated genes
with decreased expression in p38i-treated relative to un-
treated cultured huSCs: LIMS1, CRYAB, ENG, ENO3, LRP1,
and SERPINE1. Of these, expression of CRYAB, ENG, LRP1,
and SERPINE1 also was reduced by more than 50% in
p38i-treated huSCs relative to quiescent huSCs. Based on
these unbiased analyses of genome expression data, we pro-
pose that these genes in particular may function as impor-
tant regulators of huSC self-renewal downstream of p38.DISCUSSION
In this study, we used a unique profile of surface markers to
identify and prospectively isolate huSCs from surgical spec-
imens. Importantly, these markers were observed to be ex-
pressed in situ by huSCs associatedwithwhole human skel-
etal muscle fibers. Additionally, the marker profile used in
this study was able to prospectively identify huSCs from
each of three different muscles analyzed and from subjects
of various ages. These markers, therefore, represent a repro-
ducible and broadly applicable signature of huSCs. Addi-
tional analysis of huSC markers may allow simplification
of the sorting strategy presented here. For instance, CD31uthors
may redundantly identify CD34-expressing endothelial
cells and may not be necessary to isolate a pure population
of huSCs. As in previous studies (Bareja et al., 2014; Pisani
et al., 2010b), we found that the predominant myogenic
population did not express CD34. In contrast to previous
studies, however, we found little evidence for a second
myogenic population within the CD34-expressing cell
population. Analysis ofmyogenicmarker expression in sin-
gle cells and clones revealed an absence of spontaneous
myogenic activity within CD34+ cells. Future studies are
required to determine what technical variables account
for differences in the characterization of the myogenic po-
tential of CD34-expressing progenitors in human muscle.
We report an RNA-seq-based characterization of huSCs,
including prospectively isolated quiescent huSCs analyzed
immediately after sorting. A number of observations stem-
ming fromour studies support the characterization of these
cells as quiescent. Most notably, these cells were non-
dividing upon isolation, as clearly manifested in our
time-lapse microscopy studies. Indeed, although the isola-
tion and culture in high-mitogen conditions induces these
cells to activate, the huSCs typically did not undergo their
first division until after more than 3 days in culture. The
RNA-seq data provide additional confirmation of the quies-
cent nature of the prospectively isolated huSCs, which ex-
pressed low levels of numerous proliferation-related genes
relative to the cultured huSCs. That these purified huSCs
are functionally quiescent is not to say that they are iden-
tical to the huSCs in vivo. In fact, we know that the process
of isolating the cells, which takes 5–6 hr on average and in-
volves physical and enzymatic perturbations of the cell and
its environment, is enough to induce biochemical changes
within the huSCs. The extent of these differences, however,
is difficult to assess given that themost thorough character-
izations of the cells, such as RNA-seq, obviously cannot be
performed on cells in vivo. Still, we know from several
studies of SC quiescence in mouse that characterizations
of FACS-purified cells can offer insight into the biology of
SC quiescence in vivo (Cheung et al., 2012; Hausburg
et al., 2015; Liu et al., 2013; Rodgers et al., 2014).
These studies add to a growing body of information
related to the role of p38MAPK signaling in skeletal muscle
progenitor cells. Over a decade ago, a requirement for p38
in the regulation of rodent myoblast differentiation was
defined (Cuenda and Cohen, 1999; Zetser et al., 1999).
Based on these prior studies, the functions of p38 MAPK
are clearly diverse and complex. p38 activation correlates
with rodent SC activation, and pharmacologic inhibition
of p38a/b can promote muscle progenitor cell-cycle exit
(Jones et al., 2005). Intriguingly, and somewhat paradoxi-
cally, genetic absence of p38a, the dominant p38 isoform
regulating the myogenic program in mice (Lovett et al.,
2010), enhances proliferative expansion of the murine SCStem Cellpopulation postnatally and in response to injury, although
p38a is not absolutely required for myogenic differentia-
tion in vivo (Brien et al., 2013). That the p38a isoform is
not required for differentiation may be due to redundant
functions of p38b or ɣ isoforms, both of which are ex-
pressed in muscle and are capable of independently regu-
lating muscle progenitor differentiation (Wang et al.,
2008). Our studies suggest that, in humans, there is a
switch that occurs in the activation of p38 as SCs are acti-
vated in culture, akin to the activation of p38 observed
in mouse (Jones et al., 2005), going from an inactive
unphosphorylated form in quiescent huSCs to an active
phosphorylated form in cultured huSCs. Altogether, our
data and previously published studies of p38 in rodent
muscle progentiors support a model in which inhibition
of p38 activity promotes exponential growth of progeni-
tors by maintaining an undifferentiated fate. This model
seems to be conserved between mice and humans. We
further demonstrate that pharmacologic manipulation of
p38 signaling can be leveraged for enhancement of both
ex vivo expansion and subsequent in vivo engraftment of
huSCs.
In our investigation, transplantation of huSCs expanded
in the presence of p38i, generated more chimeric muscle
fibers, and self-renewed huSCs in comparison to freshly
isolated cells.Whatmight account for the enhanced regen-
erative potential of expandedhuSCs?Onepossibility is that
the activated state of expanded cells relative to quiescent
cells enabled the expanded cells to proliferate more during
the course of muscle regeneration. In previous studies of
culturedmouse SCs, this phenomenonmay not haveman-
ifested as efficient engraftment because activation coin-
cided with differentiation. By divorcing SC activation
from differentiation, p38 inhibition may have revealed an
increased engraftment potential of activated relative to
quiescent cells. This possibility is particularly interesting
given thatweobserved slower activationkinetics inpurified
huSCs relative to what has been reported for their mouse
counterparts (Rodgers et al., 2014). An alternative explana-
tion for the enhanced regenerative potential of the
expanded huSCs is that p38 inhibition induces an epige-
netic change in the cultured cells that promotes their
engraftment potential. This hypothesismay relate to recent
observations in aforementioned studies of mouse SCs,
which showed an improved function in aged mouse SCs
following treatment with a p38 inhibitor (Bernet et al.,
2014; Cosgrove et al., 2014). The huSCs used in our study
were isolated from donors with an age that greatly exceeds
that of evenagedmice. It is, therefore, plausible thathuman
adult SCs exhibit a favorable response to treatment with
p38i analogous to that observed in SCs from aged mice.
Although the mechanisms of this epigenetic restoration
of SC function have not been elucidated, our analysis ofReports j Vol. 5 j 621–632 j October 13, 2015 j ª2015 The Authors 629
the gene expression changes stimulated by p38 inhibition
identified several intriguing candidate regulators, in-
cluding ENG, CRYAB, and SERPINE1. Our current under-
standing of the functions of these proteins suggests a
plausible role for each in the aging of huSCs. ENG encodes
endoglin, a membrane glycoprotein important in TGF-b
signal transduction (Cheifetz et al., 1992). Increased
expression of endoglin has been associated with aging phe-
notypes within endothelial and myeloid lineages (Aristor-
ena et al., 2014; Blanco and Bernabeu, 2011), and excessive
TGF-b signaling has been linked to impaired self-renewal of
mouse SCs in the context of aging and chronic disease (Bi-
ressi et al., 2014; Carlson et al., 2008). Alpha-crystallin B
chain (CRYAB) is a small heat shock protein, decreased
expression ofwhichhas been linked to improved outcomes
following cardiac ischemia in aged mice (Benjamin et al.,
2007). SERPINE1, also known as plasminogen activator in-
hibitor-1 (PAI-1), is upregulated in senescent human cells
and in various tissues of progeroid mouse models,
including skeletal muscle (Baker et al., 2011; Mu and Hig-
gins, 1995). Remarkably, genetic or pharmacologic inhibi-
tion of PAI-1 has been shown to improve organ function
and extend the lifespan of progeroid mice (Eren et al.,
2014). Future studies will be important to define the spe-
cific role of these genes during aging and muscle regenera-
tion as regulators of huSCs downstream of p38 MAPK
signaling.EXPERIMENTAL PROCEDURES
Human Skeletal Muscle Specimens
Surgical specimens of human skeletal muscle were isolated in
accordance with the Stanford Institutional Review Board. All ex-
periments, unless otherwise noted, were performed using speci-
mens of latissimus dorsimuscle. Additional details are included in
the Supplemental Experimental Procedures.
HuSC Isolation
Human skeletal muscle tissue was first minced and incubated in
collagenase II (750 U/ml, Worthington Biochemical) in Ham’s
F10 medium supplemented with 10% horse serum (Invitrogen)
and 1% penicillin-streptomycin (Omega Scientific) at 37C for
90 min in a shaking water bath (60 rpm). The digested muscle
was washed in F10 with 10% horse serum and digested further
in a shaking water bath at 37C for 30 min in collagenase II
(100 U/ml) and dispase (2 U/ml, Gibco) in F10 with 10% horse
serum. Subsequent steps in the isolation procedure are detailed
in the Supplemental Experimental Procedures.
Human Muscle Fiber Explants and
Immunofluorescence Analysis
Human skeletal muscle specimens were incubated in collagenase
(500 U/ml) in Ham’s F10 supplemented with 10% horse serum
and 1% penicillin-streptomycin for 80 min in a shaking water630 Stem Cell Reports j Vol. 5 j 621–632 j October 13, 2015 j ª2015 The Abath. Tissue was then triturated with a glass Pasteur pipet to sepa-
rate singlemuscle fibers. Additional details are included in the Sup-
plemental Experimental Procedures.
HuSC Culture
Slides or plates were coated with extracellular matrix protein
(ECM, Sigma) at a concentration of 1:500 (v/v) in DMEM with
1% penicillin-streptomycin. Culture medium was a 1:1 mixture
of DMEM:MCDB supplemented with 20% FBS (Omega Scientific),
1% insulin-transferrin-selenium (ITS, Invitrogen), and 1% peni-
cillin-streptomycin. Four serum lots from two manufacturers
(Omega Scientific and Atlanta Biologicals) were tested in assays
of huSC growth and differentiation. Additional protocols for
SC culture are presented in the Supplemental Experimental
Procedures.
qRT-PCR
Freshly isolated huSCs or huSC-depleted cells were cultured for
7 days prior to analysis. For RNA isolation, cells were first rinsed
twice in PBS. Cells were then lysed and RNA was isolated using
an RNeasy Mini Kit (QIAGEN) according to the manufacturer’s in-
structions. Additional details are described in the Supplemental
Experimental Procedures.
Statistical Analysis
All statistical tests, except those involving gene set enrichment an-
alyses, were unpaired, two-tailed t tests performed using GraphPad
Prism 6.0. All error bars represent SDs, unless otherwise noted.
Data from each experiment represent statistics compiled from
true biological replicates, defined here as experiments performed
with similar, but entirely unique, biological reagents. In the
context of the human studies presented here, including the
RNA-seq analyses, replicate experiments were always performed
using cells from distinct donors.
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